Resolution –A Natural Way to Control Inflammation in Periodontal disease
The periodontal diseases are usually caused by gram-negative bacteria. The neutrophils play an important role in destruction of host tissues in periodontal disease. Pro-inflammatory mediators such as prostaglandins and leukotrienes are balanced by counter-regulatory signals provided by pro-resolving lipid mediators. This short review discusses the role of these mediators and the possibility of development of new therapeutic strategies for the control of neutrophil mediated tissue injury in periodontal disease.
Licastro F, Candore G, Lio D, Porcellini E, Colonna-Romano G, Franceschi C, et al. Innate immunity and inflammation in ageing: a key for understanding age-related diseases. Immun Ageing. 2005;2(8):1-14.
Van Dyke TE. The management of inflammation in periodontal disease. Journal of periodontology. 2008;79(8s):1601-8.
Berlutti F, Pilloni A, Pietropaoli M, Polimeni A, Valenti P. Lactoferrin and oral diseases: current status and perspective in periodontitis. Annali di Stomatologia. 2011;2(3-4):10.
Filoche S, Wong L, Sissons C. Oral biofilms: emerging concepts in microbial ecology. Journal of dental research. 2010;89(1):8-18.
Serhan CN, Yang R, Martinod K, Kasuga K, Pillai PS, Porter TF, et al. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. The Journal of experimental medicine. 2009;206(1):15-23.
Hasturk H, Kantarci A, Ohira T, Arita M, Ebrahimi N, Chiang N, et al. RvE1 protects from local inflammation and osteoclast-mediated bone destruction in periodontitis. The FASEB journal. 2006;20(2):401-3.
Serhan CN. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol. 2007;25:101-37.
Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, et al. Resolvins A Family of Bioactive Products of Omega-3 Fatty Acid Transformation Circuits Initiated by Aspirin Treatment that Counter Proinflammation Signals. The Journal of experimental medicine. 2002;196(8):1025-37.
Newman MG, Takei H, Klokkevold PR, Carranza FA. Carranza’s clinical periodontology: Saunders; 2011.
Deshmukh J, Jawali MA, Kulkarni VK. Host modulation therapy–a promising new concept in treating periodontal diseases. International Journal of Dental Clinics. 2011;3(2).
Lopez R. Understanding periodontitis in adolescents: Historical background. International Journal of Dental Clinics. 2011;3(2).
Van Dyke TE. Proresolving lipid mediators: potential for prevention and treatment of periodontitis. Journal of Clinical Periodontology. 2011;38(s11):119-25.
Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O’Neill LA, et al. Resolution of inflammation: state of the art, definitions and terms. The FASEB journal. 2007;21(2):325-32.
Das UN. Lipoxins as biomarkers of lupus and other inflammatory conditions. Lipids Health Dis. 2011;10:76.
Kohli P, Levy BD. Resolvins and protectins: mediating solutions to inflammation. British journal of pharmacology. 2009;158(4):960-71.
Norling L, Serhan C. Profiling in resolving inflammatory exudates identifies novel anti‐inflammatory and pro‐resolving mediators and signals for termination. Journal of internal medicine. 2010;268(1):15-24.
Berguerand M, Klapisz E, Thomas G, Humbert L, Jouniaux A-M, Olivier JL, et al. Differential stimulation of cytosolic phospholipase A2 by bradykinin in human cystic fibrosis cell lines. American journal of respiratory cell and molecular biology. 1997;17(4):481.
Claria J, Serhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proceedings of the National Academy of Sciences. 1995;92(21):9475-9.
Zhao Y, Calon F, Julien C, Winkler JW, Petasis NA, Lukiw WJ, et al. Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase-and PPARγ-mediated mechanisms in Alzheimer’s disease models. PloS one. 2011;6(1):e15816.
Serhan C, Chiang N. Endogenous pro‐resolving and anti‐inflammatory lipid mediators: a new pharmacologic genus. British journal of pharmacology. 2008;153(S1):S200-S15.
Serhan CN, Yacoubian S, Yang R. Anti-inflammatory and pro-resolving lipid mediators. Annual review of pathology. 2008;3:279.
Van Dyke TE. Control of inflammation and periodontitis. Periodontology 2000. 2007;45(1):158-66.
Van Dyke TE. The impact of genotypes and immune reactivity on peri-implant inflammation: identification and therapeutic use of anti-inflammatory drugs and immunomodulators. Eur J Oral Implantol. 2012;5:S51-S60.
Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switching during acute inflammation: signals in resolution. Nature immunology. 2001;2(7):612-9.
Mittal A, Ranganath V, Nichani A. Omega fatty acids and resolution of inflammation: A new twist in an old tale. Journal of Indian Society of Periodontology. 2010;14(1):3.
Takano T, Clish CB, Gronert K, Petasis N, Serhan CN. Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues. Journal of Clinical Investigation. 1998;101(4):819.
El-Sharkawy H, Aboelsaad N, Eliwa M, Darweesh M, Alshahat M, Kantarci A, et al. Adjunctive treatment of chronic periodontitis with daily dietary supplementation with omega-3 Fatty acids and low-dose aspirin. Journal of periodontology. 2010;81(11):1635-43.
Ryan ME. Nonsurgical approaches for the treatment of periodontal diseases. Dental clinics of North America. 2005;49(3):611-36.
- There are currently no refbacks.
|Published by Celesta Software Pvt Ltd|